chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Penis tingled/vibrated; Headache; Fever; Chills; This spontaneous case was reported by a patient and describes the occurrence of GENITAL DISCOMFORT (Penis tingled/vibrated), HEADACHE (Headache), PYREXIA (Fever) and CHILLS (Chills) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced GENITAL DISCOMFORT (Penis tingled/vibrated), HEADACHE (Headache), PYREXIA (Fever) and CHILLS (Chills). On 17-Mar-2021, GENITAL DISCOMFORT (Penis tingled/vibrated) had resolved. On 18-Mar-2021, PYREXIA (Fever) and CHILLS (Chills) had resolved. At the time of the report, HEADACHE (Headache) outcome was unknown.            Most recent FOLLOW-UP information incorporated above includes: On 07-May-2021: Non significant follow up received on 07-MAY-2021, no new information On 15-Jun-2021: Non significant follow up received on 15-JUN-2021, no new information
A few hours later, my head and bones and muscled started hurting. I was hurting really badly when I woke up this morning. I had a little nausea and my hips felt like they were going to collapse. I started coughing and developed a fever. The muscle pain is very bad. my chest area is very uncomfortable. ( its not over my heart, its higher up) I took Tylenol that seems to be helping the muscle pain a little.
"Covidarm" day two injection site red itchy swollen lump; "Covidarm" day two injection site red itchy swollen lump; "Covidarm" day two injection site red itchy swollen lump, getting larger; "Covidarm" day two injection site red itchy swollen lump, getting larger, hot to touch; "Covidarm" day two injection site red itchy swollen lump, getting larger, hot to touch and painful; Fatigue; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the third (booster) dose of BNT162b2 (BNT162B2) (PFIZER-BIONTECH COVID-19 mRNA VACCINE Formulation: Solution for injection, Lot Number: FF2588) via an unspecified route of administration in the left arm on 03Nov2021 at 14:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis (MS) and hypothyroidism. The patient was allergic to sulfa, cooking oils and red dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine, lisinopril and hydrochlorothiazide (HCTZ), carbamazepine all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received gabapentin and prednisone and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the right arm on 03Jul2021 at 17:00 (at the age of 45-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FAC780) via an unspecified route of administration in the left arm on 21Jul2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 05Nov2021 at 07:00, the patient experienced covid arm injection site red itchy swollen lump, was getting larger, hot to touch and painful and had fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events were unknown at the time of this report.  Follow-Up (12Nov2021): Follow-up attempts are completed. No further information is expected.
COVID breakthrough. I received my 1st booster shot on 12/01/2022 and my COVID symptoms started on 04/14/ 2022 evening I had a scratchy throat which got worse by the next day. On 04/15/2022 I tested negative. On Sunday morning I was positive. I had a very sore throat, and low grade fever. After 3 days I felt like I had a cold. It lasted about a week and I recovered alone without no med.
Rash on her thighs; This is a spontaneous report received from a contactable consumer (patient). A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. She just had her second one yesterday. How soon after her second shot can she be around other people. She stated that she had a rash before she got the second shot. She doesn't really think its from the COVID shot because she has to wear depends and it is tight around her thigh and that's where the rash on an unspecified date. The outcome of event was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
One minute after injection my BP roses from 120/75 to 158/107. Also, my PR dropped below 50 and was accompanied with lightheaded ness, LOB, face turned red, and persistent aphasia. These symptoms lasted 48 hours then I felt good for approximately 12 hours before increases nausea, SOB, heavy chest set in. I am now 4 days out with bouts of increased BP with my face turning bright red for hours on end.
Left arm at site of vaccination erythemous and warm to touch. Area of erythema about the size of a softball.
Lower lip numbness within 15 min of injection. Thick feeling of tongue and inside of mouth for the next 24 hours. Benadryl help little with symptoms. No further treatment advised at this time cont to observe Benadryl as needed. Followup if symptoms increase or continue.
Patient reported on 08/30/11 at 8:14pm an adverse event regarding site of injection of ZOSTAVAX involving redness, soreness, tenderness & swelling. Advised patient to use NSAIDS (ALEVE or Ibuprofen) & Antihistamine (CLARITIN, BENADRYL, ZYRTEC).
Pediatric patient given adult dose.   No reaction or negative side effects noted as of time of reporting.
On 6/10/11, employee received the 3rd and final dose of the Hepatitis B vaccine. Patient reported to his unit to work his shift. At an unknown time, he reported not feeling well, dizzy, nauseated, and vomited x1. He was assessed at 5:15 p.m. by our psychiatric hospital physician and was referred to a local hospital for further evaluation and treatment. Patient was seen by a physician at the local hospital and was advised that he had an "allergic reaction to the Hepatitis B vaccine. No more Hep B Vaccine". Patient was able to return to work on the same day.  Note: Patient also reported that at the time of his 2nd dose of the Hep B vaccine he had a reaction stating his arm turned red, felt "hot" and anxious.
This case was reported by a pharmacist via call center representative and described the occurrence of headache in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced headache, nausea, general body pain and sickness. On an unknown date, the outcome of the headache, nausea, general body pain and sickness were unknown. It was unknown if the reporter considered the headache, nausea, general body pain and sickness to be related to SHINGRIX. Additional details were provided as follows: This case was received via click to chat. The age at vaccination was not reported. Post vaccination the patient had a headache, body aches, was nauseated and she said down sick for 3 to 4 days. Chat was abandoned when additional information was requested.
pt received covid vaccine 6m-4y dosage instead of 5y-11y dosage. incorrect vial chosen in med room.
Extreme arm pain x3d, large red hives covering upper (L) arm x3d, large amt of swelling in left arm and face x2d, arm and face warm to touch x3d, scratchy throat x2d - determined to be an anaphylactic reaction.
Patient felt very light headed after the vaccination and dropped on the floor while picking up her cellphone. As per parents possibly due to not having eaten yet since it was very early in the morning.
received the 1st dose 1/26/2021, second dose 2/16/2021  then presented to the hospital with ble weakness, syncope, and fevers on 3/25/2021 and again on 4/26/2021 Both presentations she had leukocytosis with lymphopenia. both resolved within 24 hours. infectious workup was negative. CT a/p/chest unrevealing
This case was reported by a consumer via call center representative and described the occurrence of feeling unwell in a 84-year-old male patient who received SHINGRIX for prophylaxis. In September 2018, the patient received the 1st dose of SHINGRIX. In September 2018, less than a week after receiving SHINGRIX, the patient experienced feeling unwell and pain in arm. On an unknown date, the outcome of the feeling unwell and pain in arm were recovered/resolved. It was unknown if the reporter considered the feeling unwell and pain in arm to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX on left arm. The patient received the 1st dose of SHINGRIX around 12:00 noon. The exact date was not known. The patient had pain in his left arm that evening that lasted a day or two. The patient also said he did not feel well for approximately four days following the vaccination. The reporter did not give consent to follow up. This case was 1 of the 3 cases, reported by the same reporter.
Skin lesions, confusion, dry mouth, dizziness, abdominal pain, headache. Treated with Atarax, IV antibiotics.
This spontaneous report as received via a company representative from a physician, who was notified by his immunization nurse, refers to 3 patient of unknown age and genders. No demographics or medical data provided. It was reported that in May 2014 (reported as "this month") 3 patients were vaccinated with ZOSTAVAX, dose, site and route of administration not reported. Batch, lot# and expiration date were unknown; however, it was reported that all 3 patients received vaccines from the same batch and same lot#. On an unspecified date in May 2014 patients had reactions post vaccination. The severe reactions were injection site reactions of rash, redness, swelling and itching. It was stated that the healthcare professional "have never seen such reactions before". All 3 patient were given unspecified treatment and were better at the time of the report (outcome of the adverse events assessed as "recovering/resolving"). Relatedness between use of ZOSTAVAX and the reported adverse events was unknown. The reporter stated that the office would not use ZOSTAVAX of the same lot# anymore. Additional information has been requested.
Pt developed redness, mild edema at site of MMRV vaccine on 2/5/13. Approximately 2cm area of redness and induration at site on 2/6/13. Prescribed diphenhydramine and Triamcinolone cream.
while I was standing, I felt kind of dizzy,I couldn't tell what was near or far from me ,I felt woozy; very weak; had a headache; I was very tired; I had arm pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (while I was standing, I felt kind of dizzy,I couldn't tell what was near or far from me ,I felt woozy), ASTHENIA (very weak), HEADACHE (had a headache), FATIGUE (I was very tired) and VACCINATION SITE PAIN (I had arm pain at the injection site) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039B21A and 022C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced DIZZINESS (while I was standing, I felt kind of dizzy,I couldn't tell what was near or far from me ,I felt woozy), ASTHENIA (very weak), HEADACHE (had a headache), FATIGUE (I was very tired) and VACCINATION SITE PAIN (I had arm pain at the injection site). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, DIZZINESS (while I was standing, I felt kind of dizzy,I couldn't tell what was near or far from me ,I felt woozy) and VACCINATION SITE PAIN (I had arm pain at the injection site) outcome was unknown and ASTHENIA (very weak), HEADACHE (had a headache) and FATIGUE (I was very tired) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided Patient did not see a doctor for any of the side effects. On 15-Apr-2021, the patient felt tired, weak and had a headache.   This case was linked to MOD-2021-301237 (Patient Link).
Extra dose administered 7/28/2023; Extra dose administered on 6/01/2023; This non-serious case was reported by a consumer and described the occurrence of extra dose administered in a 90-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (on 13 June 2019,received 2nd dose), Shingrix (on 13 March 2019, received 1st dose), Zostavax (on 01 January 2008, received 2nd dose) and Zostavax (on 01 February 2007, received 1st dose). Concurrent medical conditions included dementia.   On 28-JUL-2023, the patient received the 4th dose of Shingrix. On 01-JUN-2023, the patient received the 3rd dose of Shingrix. On 01-JUN-2023, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra dose administered on 6/01/2023). On 28-JUL-2023, the patient experienced extra dose administered (Verbatim: Extra dose administered 7/28/2023). The outcome of the extra dose administered and extra dose administered were unknown.   Additional Information: Receipt Date: 02-AUG-2023 The reporter mother was having dementia . The reporter just learned that the administration of two Shingrix injection to his/ her mother in last few months without the reporter consent as medical power of attorney. The reporter concern was that the patient already had 4 prior Shingrix injection prior to the last two administered. The reporter needed to speak to someone that could explain the health consequences associated with taking this many Shingrix. The patient received 2 more dose of Shingrix, which led to extra dose administered. The reporter was requested for follow up.
Dry cough - wheezing - difficulty breathing - phlegm - weak - hoarseness - dizzy - started Oct 20-11. Went to Dr. office - treated for bacterial infection w/ antibiotic & cough syrup - 10 days later had to go to ER - got chest x-ray - CT scan - breath treatment meds - antibiotic - inhaler - prednisone - cough syrup.
Tingling throughout arm and into shoulder blade on 2 occasions throughout the day. Eyes felt swollen a few hours after receiving vaccine between 1-2 pm. Symptoms went away. At around 11pm I got welts and hives all over my body but they were particularly prevalent at the vaccine site. No change in routine throughout the day nor a change in food. Largely went away by the next day around 1pm. Still experiencing slight itchiness.
Patient states that she still feels pain at the injection site. It has been 2 and a half months.
Hospital Course and Significant Findings: Patient is a 75 Y female with acute cholecystitis, COVID+ managed with IV antibiotics with some initial improvement, but had persistent pain. Eventually got IR percutaneous cholecystostomy tube and improved as expected. Progressed as expected. Diet advanced. PT evaluated and recommend HHPT, which has been set up for her. Bile cultures grew enterococcus which was resistant to cephalosporins, but sensitive to ampicillin. After discussion with pharm, switched to PO augmentin for discharge home x 7 days.
This 95 year old  female received the Pfizer Covid shot on  2/20/21    and went to the ED on  3/16/21     and was admitted  on 3/16/21 with the following diagnoses listed below. D69.6 - Thrombocytopenia, unspecified
Covid19 vaccine Pfizer: Pt received vaccine at 1620. At 1630, pt started feeling dizzy and nauseous. On on evaluation pat diaphoretic. Laid on floor with feet up. BP 113/85, P85, O2Sat 99% on room air.  After ~10 min on the floor pt stated that she was starting to feel better. Pt moved to chair and provided water to drink but did not want to eat anything (due to food allergies). After 5 min sitting up pt felt dizzy again (PB 127/88, P81, 02Sat 99% on RA). Pt brought back to floor with feet elevated. At 1700 pt sat up again. Continued to be symptomatic (BP 121/90, P 80, 02Sat 99% on RA. Pt brought to ED for further observation, report given to triage nurse. Pt. Remained alert and oriented throughout. Discharged from ED after glucose check WNL and ECG (Normal sinus rhythm with sinus arrhythmia. Rightward axis. No previous ECGs available)
My menstrual cycle started a day after the vaccine, and ever since then I have the worst cramps heaviest clotting period lasting 2-3 days more than the usual.
fever (up to 102), chills, body aches, nausea, vomiting, diarrhea, headache. Symptoms lasted from 10:00pm on 1/26/2021 until 9:00pm on 1/27/2021. Needed an Rx for zofran due to nausea. Was unable to keep down water.
4 month old received Kinrix; Supposed to be 2nd dose of DTap; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received DTPa-IPV (Kinrix) (batch number 24T2N) for prophylaxis.   On 13-MAR-2023, the patient received Kinrix. On 13-MAR-2023, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 4 month old received Kinrix) and inappropriate schedule of vaccine administered (Verbatim: Supposed to be 2nd dose of DTap). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt date: 13-Mar-2023 On 13th March 2023 a Medical Assistant informed that a 4-month old patient had received a dose of Kinrix that was supposed to be the 2nd dose of the DTap series. The Vaccine Administration Facility is the same as Primary Reporter. The reporter consented to follow up.  The 4-month-old patient received Kinrix as 2nd dose of DTap, which led to inappropriate age at vaccine administration and inappropriate schedule of vaccine administered.
High fever (102.5 - 103.7), alternate acetaminophen and ibuprofen with no effects of bringing fever down.
Information has been received from a physician concerning a 'hemeoncology' patient who was vaccinated with VARIVAX vaccine. Subsequently the patient experienced a rash. A specimen of the lesions was sent for polymerase chain reaction analysis. Assitional information has been requested.
At about 11 p.m. on March 7, 2005, my muscles started spasming and were hot. It covered my entire body. My body was aching all over. I was shaking uncontrollably. I was unable to sleep at all during the entire night. By afternoon the spasms had subsided. The morning of March 8 my temperature was 102 F. During the day my fever dropped to a low grade fever. This continued through March 9. When I woke up on March 10, my fever was gone, but my neck was stiff. I applied heat and it felt better.
2 hours after vaccine administration, patient experienced pain and swelling in the arm it was administered. Next morning (about 14 hours later) she experienced facial swelling. After 24 hours the patient experienced a rash all over her chest.
Arm - a little tender for a couple days after injection but not bad. But noticed red circle at injection site today (05/17/2021), about 3? diameter, but doesn?t hurt and doesn?t feel swollen, just red.  Listing recovery unknown below because not sore (recovered) but yes still red around injection site
Patient was 9 weeks pregnant at time of her Moderna booster vaccine on 11/2. (LMP 8/29/21 and EDD 6/5/22). She began spotting on 11/3 and had a complete miscarriage on 11/4.
Developed isolated bilateral tinnitus (first noticed around 1.5 - 2 weeks after 1st dose of COVID vaccine was administered on 1/9/2021). Have since been seen by neurologist and had audiology exam (both completely normal on 2/23/2021). Isolated tinnitus persists, but does not interfere with sleep or work or life, and has not worsened after 2nd dose of COVID vaccine.
5 days after injection she awoke to large area of swelling on her forehead.  Resolved after a few days
second dose he experienced myalgia; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of myalgia in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of no adverse event (received 1st dose on an unknown date and was fine).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced myalgia (Verbatim: second dose he experienced myalgia). The outcome of the myalgia was unknown.   It was unknown if the reporter considered the myalgia to be related to Shingrix.     It was unknown if the company considered the myalgia to be related to Shingrix.   Additional Information: GSK Receipt Date: 26-JUN-2023 The patient self-reported this case. The patient received the Shingrix vaccines about a year ago from reporting. The reporter consented to follow up.